Proteasome inhibitors therapeutic strategies for cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 73-82

  D'Alessandro, Annamaria ^a,d,e   Pieroni, Luisa ^a,b,c   Ronci, Maurizio ^a,b,c   D'Aguanno, Simona ^a,d,e   Federici, Giorgio ^d,e   Urbani, Andrea ^a,b,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Centro Studi sull'Invecchiamento CeSI   (Italy)

^d TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cancer; Proteasome Inhibitors (PIs); Protein degradation disorders

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE DECARBOXYLASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYCLINE; EPIGALLOCATECHIN GALLATE; EPOXOMICIN; GLIOTOXIN; HEAT SHOCK PROTEIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; MULTIDRUG RESISTANCE PROTEIN; PEPTIDE ALDEHYDE INHIBITOR; PEPTIDE BORONIC ACID BASED INHIBITOR; POLYPHENOL; PROTEASOME INHIBITOR; SOMATOMEDIN; SULFONE DERIVATIVE; TMC 95A; UBIQUITIN; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; PROTEASOME; PROTEINASE INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANCE; NONHUMAN; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR GROWTH; TUMOR VASCULARIZATION; UBIQUITINATION; ANIMAL; DRUG ANTAGONISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 62749162681     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002452     Document Type: Review

References (151)

1. Papapostolou D, Reboud-Ravaux M. Proteasome and proteolysis. J Soc Biol 2004; 198: 263-278.
2. Hilt W, Wolf DH, eds. Proteasomes: The World of Regulatory Proteolysis. Austin and Georgetown, Texas: Eurekah.com/Landes Bioscience Publishing Company 2000; 1-391.
3. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
4. Seglen PO, Bohley P. Autophagy and other vacuolar protein degradation mechanisms. Experientia 1992; 48: 158-172.
5. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006; 443: 780-786.
6. Varshavsky A. The ubiquitin system. Trends Biochem Sci 1997; 22: 383-387.
7. Hilt W, Wolf DH. Proteasomes: Destruction as a programme. Trends Biochem Sci 1996; 21: 96-102.
8. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998; 95: 2727-2730.
9. Ciechanover A. The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 1998; 17: 7151-7160.
10. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia. Blood 2008; 111 (9): 4752-4763.
11. Zwickl P, Voges D, Baumeister W. The proteasome: A macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1501-1511.
12. Kisselev AF, Goldberg AL. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 2001; 8: 739-758.
13. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8: 307-315.
14. Mitchell BS. The proteasome: An emerging therapeutic target in cancer. N Engl J Med 2003; 348: 2597-2598.
15. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58: 4342-4348.
16. Delic J, Masdehors P, Omura S, et al. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 1998; 77: 1103-1107.
17. Masdehors P, Omura S, Merle-Béral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 1999; 105: 752-757.
18. Kudo Y, Takata T, Ogawa I, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000; 6: 916-923.
19. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
20. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001; 82: 110-122.
21. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100:11-17.
22. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-3540.
23. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
24. Cusack JC Jr, Liu R, Xia L, et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006; 12: 6758-6764.
25. Vinitsky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry 1992; 31: 9421-9428.
26. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001; 21: 245-273.
27. Bogyo M, Shin S, McMaster JS, Ploegh HL. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol 1998; 5: 307-320.
28. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature 1998; 392: 618-622.
29. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
30. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-15676.
31. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22(2): 304-311.
32. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 1999; 96: 5418-5422.
33. Lynas JF, Harriott P, Healy A, McKervey MA, Walker B. Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals). Bioorg Med Chem Lett 1998; 8: 373-378.
34. Chatterjee S, Dunn D, Mallya S, Ator MA. P'-extended alpha-ketoamide inhibitors of proteasome. Bioorg Med Chem Lett 1999; 9: 2603-2606.
35. Lum RT, Nelson MG, Joly A, et al. Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides. Bioorg Med Chem Lett 1998; 8: 209-214.
36. Verma R, Peters NR, D'Onofrio M, et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 2004; 306:117-120.
37. Deshaies, R., King, R., Verma, R.: US20050203063 (2005).
38. Fenteany G, Standaert RF, Lane WS, et al. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268: 726-731.
39. Meng L, Mohan R, Kwok BH, et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96:10403-10408.
40. Meng L, Kwok BH, Sin N, Crews CM. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999; 59: 2798-2801.
41. Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: A useful tool for understanding proteasome biology. Bioorg Med Chem Lett 1999; 9: 2283-2288.
42. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. Towards subunit-specific proteasome inhibitors: Synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol 1999; 6: 811-822.
43. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome: TMC-95A complex: A non-covalent proteasome inhibitor. J Mol Biol 2001; 311: 543-548.
44. Orlowski RZ. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 1999; 6: 303-313.
45. Hanada M, Sugawara K, Kaneta K, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot 1992; 45: 1746-1752.
46. Sugawara K, Hatori M, Nishiyama Y, et al. Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J Antibiot 1990; 43: 8-18.
47. Kroll M, Arenzana-Seisdedos F, Bachelerie F, et al. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem Biol 1999; 6: 689-698.
48. Nam S, Smith DM, Dou Q. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276: 13322-13330.
49. Dou, Q. P., Chan, T.-H., Smith, D. M.: US20080015248 (2008).
50. Fenteany G, Standaert RF, Lane WS, et al. Lactacystin Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995; 268: 726-731.
51. Feling RH, Buchanan GO, Mincer TJ, et al. Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 2003; 42: 355-357.
52. Schreiber, S. L., Standaert, R. F., Fenteany, G., Jamison, T. F.: US20060052424 (2006).
53. Danishefsky, S. J., Endo, A.: US20060287520 (2006).
54. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983; 33: 389-396.
55. Swenson KI, Farrell KM, Ruderman JV. The clam embryo protein cyclin A induces entry into M phase and the resumption of meiosis in Xenopus oocytes. Cell 1986; 47: 861-870.
56. Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature 1991; 349: 132-138.
57. Koepp DM, Harper JW, Elledge SJ. How the cyclin became a cyclin: Regulated proteolysis in the cell cycle. Cell 1999; 97: 431-434.
58. Machiels BM, Henfling ME, Gerards WL, et al. Detailed analysis of cell cycle kinetics upon proteasome inhibition. Cytometry 1997; 28: 243-252.
59. Ciechanover A, DiGiuseppe JA, Bercovich B, et al. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA 1991; 88: 139-143.
60. Maki CG, Huibregtse JM, Howley PM. in vivo Ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56: 2649-2654.
61. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
62. Lopes UG, Erhardt P, Yao R, Cooper GM. p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893-12896.
63. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
64. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071.
65. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-663.
66. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004; 100: 1578-1589.
67. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-κB in Waldenstrom Macroglobulinemia. Blood 2008; 111: 5068-5077.
68. Baldwin, A. S., Cusack, J. C., Mayo, M. W., Wang, C.-Y.: US20070110828 (2007).
69. Manning, A. M., Mercurio, F., Amit, S., Ben-neriah, Y., Davis, M., Hatzubai, A., Yaron, A., Alkalay, I., Ciechanover, A.: US20060084691 ( 2007).
70. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol 1999; 17: 739-779.
71. Figueiredo-Pereira ME, Berg KA, Wilk S, A new inhibitor of the chymotrypsin-like activity of the multicatalytic proteinase complex (20S proteasome) induces accumulation of ubiquitin-protein conjugates in a neuronal cell. J Neurochem 1994; 63: 1578-1581.
72. Schubert U, Anton LC, Gibbs J, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000; 404: 770-774.
73. Bush KT, Goldberg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997; 272: 9086-9092.
74. Tiligada E. Chemotherapy: Induction of stress responses. Endocr Relat Cancer 2006; 13:115-124.
75. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
76. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem Sci 2006; 31: 164-172.
77. Ciocca DR, Oesterreich S, Chamness GC, McGuire WL, Fuqua SA. Biological and clinical implications of heat shock protein 27,000 (Hsp27): A review. J Natl Cancer Inst 1993; 85: 1558-1570.
78. Yamamoto Y, Kume M, Yamaoka Y. Implications of heat shock proteins during liver surgery and liver perfusion. Recent Results Cancer Res 1998; 147:157-172.
79. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103.
80. Holzer AM, Martiniuk F, Levis WR. Heat-shock proteins as drugs: Potential applications in cancer, infections, and autoimmune and atopic diseases. J Drugs Dermatol 2007; 6: 393-399.
81. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, et al. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995; 217: 1070-1077.
82. Orlowski RZ, Eswara JR, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58: 4342-4348.
83. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res. 2008; 14:1649-1657.
84. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-860.
85. Masdehors P, Omura S, Merle-Beral H, et al. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome specific inhibitor lactacystin. Br J Haematol 1999; 105: 752-757.
86. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-860.
87. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007; 67: 4981-4988.
88. Nasoff, M., Deveraux, Q. L., Knee, D. A., Aza-Blanc, P., Hampton, G. M., Wagner, K.: US20050079172 (2005).
89. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
90. Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220-4229.
91. Vink J, Cloos J, Kasper JL. Proteasome inhibition as novel treatment strategy in leukemia. B J Hemat 2006; 134: 253-262.
92. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
93. Brignole C, Marimpietri D, Pastorino F, et al. Effect of Bortezomib on human neuroblastoma cell growth. Apoptosis and angiogenesis. JNCI 2006; 98: 1142-1157.
94. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.
95. Strömblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996; 98: 426-433.
96. Strömblad S, Cheresh D. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996; 11: 881-885.
97. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65-77.
98. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68: 499-508.
99. Kumeda SI, Deguchi A, Toi M, Omura S, Umezawa K. Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res 1999; 19: 3961-3968.
100. Oikawa T, Sasaki T, Nakamura M, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-248.
101. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639.
102. Nawrocki S, Bruns C, Harbison M, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenographs. Mol Cancer Therapeut 2002; 1: 1243-1253.
103. de Bono JS, Rowinsk EK. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2002; 8: 19-26.
104. Piperdi, B.: US20060084691 (2006).
105. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994; 78: 761-771.
106. Cascio P, Hilton C, Kisselev AF, Rock KL, Goldberg AL. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 2001; 20: 2357-2366.
107. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
108. Wang J, Maldonado MA. The ubiquitin-proteasome system and its role in rnflammatory and autoimmune diseases. Cell Mol Immunol 2006; 3: 255-261.
109. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18: 3-10.
110. Grisham MB, Palombella VJ, Elliott PJ, et al. Inhibition of NF-kappa B activation in vitro and in vivo: Role of 26S proteasome. Methods Enzymol 1999; 300: 345-363.
111. Agoulnik, S., Akasaka, K., Fang, F., Harmange, J.-C., Hawkins, L., Jiang, Y., Johannes, C., Li, X.-Y., McGuinness, P., Murphy, E. A., Schiller, S., Vermeulen, M., Wu, J.: US20050101781 (2005).
112. Chen JJ, Huang WC, Chen CC. Rregulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein. Mol Biol Cell 2005; 16: 5579-5591.
113. Sinn DI, Lee ST, Chu K, et al. Proteasomal inhibition in intracerebral hemorrhage: Nneuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007; 58: 12-18.
114. Wu, J., Wang, X.: US20020049157 (2002).
115. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-193.
116. Wang CY, Cusack JCJ, Liu R, Baldwin ASJ. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-417.
117. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: Control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470: 55-62.
118. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
119. Cusack JCJ, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-3540.
120. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001; 100: 11-17.
121. Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003; 102: 3765-3774.
122. Anderson, K.C., Hideshima, T., Mitsiades, C.S., Mitsiades, N.: US20050267037 (2005).
123. Wheatley DN. Controlling cancer by restricting arginine availability arginine-catabolizing enzymes as anticancer agents. Anticancer Drugs 2004; 15: 825-833.
124. Wheatley DN, Campbell E. Arginine catabolism, liver extracts and cancer. Pathol Oncol Res 2002; 8: 18-25.
125. Cendan JC, Souba WW, Copeland EM 3rd, Lind DS. Increased L-arginine transport in a nitric oxide-producing metastatic colon cancer cell line. Ann Surg Oncol 1996; 3: 501-508.
126. Tepic, S., Pyk, P.: US5851985 (1998).
127. Tepic, S., Pyk, P.: US20030017146 (2003).
128. Tainton KM, Smyth MJ, Jackson JT, et al. Mutational analysis of P-glycoprotein: Suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 2004; 11: 1028-1037.
129. Fujita T, Washio K, Takabatake D, et al. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein-mediated multidrug resistance. Int J Cancer 2005; 117: 670-682.
130. Zhang Y, Shi Y, Li X, et al. Proteasome inhibitor MG132 reverses multidrug resistance of gastric cancer through enhancing apoptosis and inhibiting P-gp. Cancer Biol Ther 2008; 7(4): 540-6.
131. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trens Cell Biol 2000; 10: 524-530.
132. Anderson, K.C., Bradner, J. E., Greenberg, E. F., Hideshima, T., Kwiatkowski, N. P., Mazitschek, R., Schreiber, S. L., Shaw, J., Haggarty, S. J.: US20060239909 (2006).
133. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C. HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res 2007; 17: 195-211.
134. Jones P, Steinkühler C. From natural products to small molecule ketone histone deacetylase inhibitors: Development of new class specific agents.Curr Pharm Des 2008; 14: 545-561.
135. Wittich S, Scherf H, Xie C, et al. Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines. Anticancer Drugs 2005; 16: 635-643.
136. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93: 5705-5708.
137. Frankel, S. R., Deutsch, P. J., Randolph, S., Fine, B.: US20070197473 (2007).
138. Guédat P, Colland F. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 2007; 8:14.
139. McNaught KS, Björklund LM, Belizaire R, et al. Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 2002; 13: 1437-1441.
140. Lee G, Junn E, Tanaka M, Kim YM, Mouradian MM. Synphilin-1 degradation by the ubiquitin-proteasome pathway and effects on cell survival. J Neurochem 2002; 83: 346-352.
141. McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006; 60: 243-247.
142. Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006; 66: 529-534.
143. Fornai F, Lenzi P, Gesi M, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci 2003; 23: 8955-8966.
144. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. Wide distribution of 3H(-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis 1998; 19: 1771-1776.
145. Wilk S, Figueiredo-Pereira ME. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 1993; 47: 306-313.
146. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8(4): 333-338.
147. Iqbal M, Chatterjee S, Kauer JC, et al. Potent inhibitors of proteasome. J Med Chem 1995; 38: 2276-2277.
148. Spaltenstein A, Leban JJ, Huang JJ, et al. Design and synthesis of novel protease inhibitors. Tripeptide α-pm, β′-epoxyketones as nanomolar inactivators of the proteasome. Tetrahedron Lett 1996; 37: 1343-1346.
149. Bogyo M, Shin S, McMaster JS, Ploegh HL. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol 1998; 5: 307-320.
150. Loidl G, Groll M, Musiol HJ, et al. Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol 1999; 6: 197-204.
151. Loidl G, Musiol HJ, Groll M, Huber R, Moroder L. Synthesis of bivalent inhibitors of eucaryotic proteasomes. J Pept Sci 2000; 6: 36-46.